Alpha Fetoprotein, Total and L3 Percent
Also known as: AFP L3
Use
The test is used for the surveillance and monitoring of hepatocellular carcinoma. The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated serum AFP-L3 percent values are associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. However, results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
Special Instructions
Results obtained with different assay methods or kits cannot be used interchangeably. For pregnant females, the result is not interpretable as a tumor marker.
Limitations
Results obtained through this method cannot be used interchangeably with those from different assay methods or kits. The results are not absolute evidence of the presence or absence of malignant disease. For pregnant females, the test result is not interpretable as a tumor marker.
New York Approved
Methodology
Immunoassay (Other)
Biomarkers
LOINC Codes
- 1834-1
- 42332-7
- 1834-1
- 42332-7
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP standard transport tube
Collection Instructions
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer serum to a transport tube.
Causes for Rejection
Plasma
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 5 days |
| Frozen | 3 months |